<DOC>
	<DOCNO>NCT00694057</DOCNO>
	<brief_summary>This phase II , double-blind , randomize , placebo-controlled study safety , tolerance activity HE3286 patient type 2 diabetes mellitus . Patients receive stable metformin drug-naive receive study treatment ( HE3286 placebo ) treatment period 12-weeks .</brief_summary>
	<brief_title>Safety , Tolerance Activity HE3286 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Hollis-Eden Pharmaceuticals , Inc. develop new class therapeutic treatment Type 2 diabetes . The investigational drug , HE3286 , hold potential first new class insulin sensitizer potentially novel mechanism action may improve current therapeutic option available T2DM patient . This phase II , double-blind , randomize , placebo-controlled study safety , tolerance activity HE3286 patient type 2 diabetes mellitus . Patients receive stable metformin drug-naive receive study treatment ( HE3286 placebo ) treatment period 12-weeks . Changes hemoglobin A1c ( HbA1c ) assess treatment period 12-weeks .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Main Patient diagnosis Type 2 Diabetes Mellitus ( T2DM ) Patient must ) stable dose metformin monotherapy least 10 week prior screen ; b ) drugnaive , define never receive drug treatment T2DM receive antidiabetic drug therapy 3 month prior screen . Patient fast blood glucose level ≤ 225 mg/dL screening ( ≤ 255 mg/dl drugnaive patient ) ; Patient HbA1c level &gt; 7.5 % ( 7.0 10.5 % drugnaive patient ) screen ; Patient BMI 2837 kg/m2 female 2839 kg/m2 male Main Patient history clinically significant cardiovascular disease ( include coronary artery disease ) , clinically significant hepatic , respiratory renal abnormality within 6 month prior screen ; Patient unstable diabetic complication require treatment ongoing active intervention ; Patient history long term insulin therapy within past year ; Patient therapy rosiglitazone , pioglitazone , exendin4 sitagliptin , alone combination within 6 month prior screen ; Patient clinically significant abnormality laboratory result screen ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Metformin</keyword>
	<keyword>HbA1c</keyword>
</DOC>